Biggest Gainning Stocks Are Costing Your Business Money (BDSI, LNCE, IMUC,ENMD)

Los Angelas, CA -- (SBWIRE) -- 09/07/2012 -- BioDelivery Scien (NCM:BDSI) is very active today and traded between $5.04 - 5.66 with total traded volume of 1374362 shares. At a current price of 5.61, BDSI is +0.59 - +11.75% from the previous close of $5.02. Moreover, At Current Market Price, BDSI is in distance of +18.06% from its 50-day Moving Average price of $4.752 and +50.37% from its 200-day Moving Average price of $3.7308. BioDelivery Sciences International Inc.shot up 12 percent to close at $5.61. The Raleigh pharmaceutical company has recovered strongly from late last year, when its shares briefly dipped below $1.

Collect Your Free Copy Today Click Here

Snyder's-Lance, I (NasdaqNM:LNCE) is very active today and traded between $23.82 - 25.32 with total traded volume of 577743 shares. At a current price of 25.11, LNCE is +2.61 - +11.60% from the previous close of $22.50. Moreover, At Current Market Price, LNCE is in distance of +8.54% from its 50-day Moving Average price of $23.1343 and +2.51% from its 200-day Moving Average price of $24.4963. Snyder's-Lance, Inc. 12.0% HIGHER; announced plans to acquire Snack Factory, LLC and certain affiliates, for $340 million in cash. This includes approximately $60 million of net present value of future tax benefits. Snyder's-Lance, Inc. (Snyder's-Lance) expects to close the transaction early in the fourth quarter.

Get a free trend analysis on LNCE Click Here

Shares of ImmunoCellular Th (AMEX:IMUC) are trading at $3.23 and is +11.65% from its 50-day Moving Average price of $2.8929 and +9.16% from its 200-day Moving Average price of $2.9589. The average trading volume is 654641 shares and its market capitalization is $131.2M.ImmunoCellular Therapeutics is showing big gains on Thursday after the Maxim Group initiated coverage of the company with a Buy rating and a price target of $18.00. Shares were up 12% to $3.25 at noon. The company`s lead product is a potential cancer vaccine called ICT-107 that completed enrollment on Wednesday of a Phase II trial for the treatment of glioblastoma. The drug is intended for use post-chemotherapy as a therapeutic, helping the body`s immune system combat remaining cancer cells. A previous Phase I study demonstrated that the drug may improve patient survival before the cancer can regain strength. Interim data is expected in the first quarter of 2013.

Sing Up Here For Our Full Analysis

EntreMed, Inc. (NCM:ENMD) is very active today and traded between $1.71 - 1.91 with total traded volume of 32192 shares. At a current price of 1.91, ENMD is +0.19 - +11.05% from the previous close of $1.72. Moreover, At Current Market Price, ENMD is in distance of -3.77% from its 50-day Moving Average price of $1.9849 and -5.10% from its 200-day Moving Average price of $2.0127. EntreMed, Inc. ENMD +11.05% , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today the publication of an article by Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute in Boston, entitled "ENMD-2076, an Oral Inhibitor of Angiogenic and Proliferation Kinases, Has Activity in Recurrent, Platinum Resistant Ovarian Cancer," in the European Journal of Cancer.

Sign Up For Very Time Sensitive Stock Alert

Disclaimer:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com